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Abstract
Chip profiling of a p53 temperature-sensitive tumor
model identified SAK (Snk/Plk-akin kinase), encoding a
new member of polo-like kinases (PLKs), as a gene
strongly repressed bywild-type p53. Further characteri-
zation revealed that SAK expression was downregu-
lated by wild-type p53 in several tumor cell models.
Computer search of a 1.7-kb SAK promoter sequence
revealed three putative p53 binding sites, but p53 failed
to bind to any of these sites, indicating that SAK
repression by p53 was not through a direct p53 binding
to the promoter. Transcriptional analysis with lucifer-
ase reporters driven by SAK promoter deletion frag-
ments identified SP-1 and CREB binding sites, which
together conferred a two-fold SAK repression by p53.
However, the repression was not reversed by cotrans-
fection of SP-1 or CREB, suggesting a lack of inter-
ference between p53 and SP-1 or CREB. Significantly,
p53-mediated SAK repression was largely reversed in a
dose-dependent manner by Trichostatin A, a potent
histone deacetylase (HDAC) inhibitor, suggesting an
involvement of HDAC transcription repressors in SAK
repression by p53. Biologically, SAK RNA interference
(RNAi) silencing induced apoptosis, whereas SAK
overexpression attenuated p53-induced apoptosis.
Thus, SAK repression by p53 is likelymediated through
the recruitment of HDAC repressors, and SAK repres-
sion contributes to p53-induced apoptosis.
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Introduction
In response toDNAdamage or other cellular stresses, p53 is
activated and induces growth arrest or apoptosis, depend-
ing on the severity of the damage and the cell context, which
tends to maintain genome stability and prevent cancer
development [1,2]. p53 is a transcription factor, and it
achieves these functions mainly through its transactivation
as well as transrepression of its downstream target genes
[3,9]. The ability of p53 to induce growth arrest is usually
mediated through transactivation of several critical target
genes, such asWaf-1/p21, 14-3-3r, and PTGF-b [4–7], for G1
and G2 arrest. However, p53 induces apoptosis by trans-
activation of selected target genes involved in the mitochon-
drial or death receptor signal pathways in a tissue- and cell
type–specific manner [8,9]. The p53 downstream target
genes involved in the mitochodrial signal pathway include
BAX, PIGs, NOXA, PUMA, p53AIP, [10–15] and in the
death receptor pathway include KILLER/DR5, FAS/APO1,
and PIDD [16–18]. In addition, p53 has been shown to
negatively regulate cell survival genes such as survivin,
IGF1R, and bcl-2 [19–21] with a net outcome of facilitating
apoptosis induction.
It has been well demonstrated that p53 transactivates its
targets through a direct binding to its consensus sequence,
consisting of two repeats of 10-bp motif 5V-PuPuPuC(A/T)(T/
A)GPyPyPy-3Vseparated by 0 to 13 nucleotides, located in the
promoter region or the first few introns of a target gene [31]. In
contrast, p53 consensus binding sites are not found within a
vast majority of promoters repressed by p53, although a recent
report showed that p53 repressed the MDR1 promoter through
a direct binding to a novel p53 binding site RRRCWRRRCW
N(0–13) RRRCWRRRCW [22].
In an attempt to identify genes responsive to p53-induced
apoptosis, we profiled H1299 human lung carcinoma cells with
the Affymatrix U95 gene chip [23] and report here a novel
p53-repressed gene, SAK (Snk/Plk-akin kinase), which enco-
des a new polo-like kinase (PLK). Murine SAK was originally
cloned as a homolog to Drosophila polo kinase involved in cell
proliferation [24]. Constitutive expression of murine SAK sup-
pressed cell growth and induced multinucleation [25]. Knock-
out SAK produced embryonic lethality. The SAK/ embryo at
E8.5 is smaller than wild-type or heterozygous littermates.
The embryo is arrested with an increase both in mitotic and
apoptotic cells [26]. Human SAK that is highly expressed
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in testis was cloned in 1997 [27] and was recently found to
have kinase activity and to be tyrosine-phosphorylated by
Tec tyrosine kinase [36]. Human SAK was highly ex-
pressed in colon cancers, compared to adjacent normal
intestinal mucosa [35].
We found that downregulation of SAK expression is p53-
dependent. p53-induced SAK repression is neither mediated
through direct binding to its consensus sequences nor
through an interference of p53 with other transcription fac-
tors, but rather through the recruitment of histone deacety-
lase (HDAC) repressor. Biologically, SAK silencing by RNAi
induces apoptosis, whereas SAK overexpression attenuates
p53-induced apoptosis, suggesting that SAK repression
contributes to p53-induced apoptosis.
Materials and Methods
Cell Culture and Treatment
H1299-V138, a human lung carcinoma cell line trans-
fected with a temperature-sensitive mutant p53 (containing
an alanine-to-valine point mutation), and its vector control
(H1299/Neo) were kindly provided by Gr. Jiandong Chen
(H. LeeMoffitt CancerCenter andResearch Institute, Tampa,
FL) [28]. The H460 lung carcinoma line and H460/E6 (stably
transfected with the human papilloma virus E6 gene) were
obtained fromDr. Wafik El-Deiry (University of Pennsylvania,
Philadelphia, PA). All other cell lines used in the study were
purchased from ATCC (Manassas, VA). The parental lung
carcinoma H1299 and H460, as well as HeLa cells, were
grown in Dulbecco’s modified Eagle’s medium with 10%
fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), whereas
H1299-V138, H1299/Neo, and H460/E6 cells were cul-
tured in the same medium plus 0.75 mg/ml G418 (Invitro-
gen). The human osteosarcoma U2-OS and Saos-2 cells
were grown in McCoy’s 5a medium with 10% FBS (Invitro-
gen). All culture media were supplemented with 100 mg/ml
streptomycin and 100 U/ml penicillin (Invitrogen). To change
p53 conformation, the culture temperature for H1299-V138
and H1299/Neo was either 39jC (nonpermissive for wild-
type p53 conformation) or 32jC (permissive for wild-type
p53). To activate p53, cells were treated with etoposide
(25 mM; Sigma, St. Louis, MO) for different periods of time.
Affymetrix Chip Profiling
H1299-V138 and H1299/Neo cells were grown at 37jC
to f70% confluency and shifted to either 32jC or 39jC for
6, 16, or 24 hours in the absence or presence of 25 mM
etoposide. Total RNA was isolated, then cRNA was synthe-
sized and subjected to chip hybridization as detailed previ-
ously [23,29] using Affymetrix (Santa Clara, CA) human
U95Av2 GeneChip A, consisting of 12,000 human genes
(Affymetrix). Scanned output files were analyzed using Affy-
metrix Microarray Suite 4.0. The expression value for each
gene was determined by calculating the average differences
of the probe pairs. Fold change was expressed by dividing
the expression value of each treatment to that of the cor-
responding control in each group, as shown in Table 1.
Northern Analysis
Northern analysis was performed as detailed previously
[30]. Briefly, total RNA was isolated from cells using Trizol
reagents (Invitrogen) and 15 mg was used for analysis. The
probes for SAK and GAPDH were made by reverse tran-
scription polymerase chain reaction (RT-PCR). Primers for
SAK were 5V-GTGGGGAAATCAAGAAACCA-3V and 5V-
GGTGGCTCCATACCCCTAGT-3V, which generated a
699-bp fragment. Primers for GAPDH were 5V-CGAGAT-
CCCTCCAAAATCAA-3V and 5V-TGTGGTCATGAGTCC
TTCCA-3V. These two cDNA fragments were subcloned
into pCR2.1 for sequence confirmation and then used as
Northern probes.
Identification of the Transcription Initiation Site and Search
for Potential p53 Binding Sites in the Promoter Region
A PCR-based 5VRACE was performed using the First-
Choice RLM-RACE kit with protocols suggested by the
manufacturer (Ambion, Austin, TX). Briefly, total RNA was
treated with calf intestinal phosphatase (CIP) to remove free
5V-phosphates from molecules of fragmented mRNA. The
RNA was then treated with Tobacco Acid Pyrophosphatase
to remove the cap structure from full-length mRNA, leaving a
5V-monophosphate. A 5V RACE adapter oligo, 5V-GAA-
CACTGCGTTTGCTGGCTTT GATGAAA-3V, which is spe-
cific for the 5V-monophosphate, was ligated to the RNA
population using T4 RNA ligase. An RT- PCR reaction then
amplified the 5Vend of the SAK mRNA using the adapter
oligonucleotide and a primer from the SAK mRNA. The 5V
RACE products were cloned into pCR2.1 vectors and the
insert fragments were sequenced. The transcription initiation
site was determined by comparing the sequences imme-
diately after the 5VRACE adapter oligonucleotide to the
Table 1. Repression of SAK Expression under Growth Arrest and Apoptotic
Conditions.
Treatment Conditions p53 Status Fold Change
Group 1 p53, 6 hours, DMSO, at 39jC Mutant 1.0
p53, 16 hours, DMSO, at 39jC Mutant 1.1
p53, 24 hours, DMSO, at 39jC Mutant 1.0
p53, 6 hours, DMSO, at 32jC Wild type 1.1
p53, 16 hours, DMSO, at 32jC Wild type 1.5
p53, 24 hours, DMSO, at 32jC Wild type 5.1
Group 2 p53, 6 hours, etoposide, at 39jC Mutant 1.0
p53, 16 hours, etoposide, at 39jC Mutant 1.0
p53, 24 hours, etoposide, at 39jC Mutant 1.1
p53, 6 hours, etoposide, at 32jC Wild type 1.0
p53, 16 hours, etoposide, at 32jC Wild type 2.2
p53, 24 hours, etoposide, at 32jC Wild type 3.6
Group 3 Neo, 6 hours, DMSO, at 39jC p53/ 1.0
Neo, 16 hours, DMSO, at 39jC p53/ 1.2
Neo, 24 hours, DMSO, at 39jC p53/ 1.2
Neo, 6 hours, DMSO, at 32jC p53/ 1.0
Neo, 16 hours, DMSO, at 32jC p53/ 1.1
Neo, 24 hours, DMSO, at 32jC p53/ 1.1
Group 4 Neo, 6 hours, etoposide, at 39jC p53/ 1.0
Neo, 16 hours, etoposide, at 39jC p53/ 1.1
Neo, 24 hours, etoposide, at 39jC p53/ 1.0
Neo, 6 hours, etoposide, at 32jC p53/ 1.2
Neo, 16 hours, etoposide, at 32jC p53/ 1.1
Neo, 24 hours, etoposide, at 32jC p53/ 1.1
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SAK gene sequence by the evidence viewer from NCBI
(Bethesda, MD). After determination of the initiation site, a
region between 1.7 kb upstream of the site and 100 bp
downstream of the site was searched for potential p53
binding elements. Fasta files for the region were uploaded
into Unix, converted to a GCG file, and searched with the
GCG program, Findpatterns. The search was conducted
for p53 consensus binding elements, RRRCWWGY-
YY(N){0,13}RRRCWWGYYY [31], and potential p53 repres-
sive elements, RRRCWRRRCW(N){0,13}RRRCWRRRCW,
suggested by Johnson et al. [22], allowing three mismatches.
Promoter Constructs and Luciferase Reporter Assays
An 1.8-kb fragment, P-00/14, containing 1698 bp of up-
stream and 102 bp of downstream sequences around the
transcription initiation site, was PCR-generated and sub-
cloned into the pGL3 luciferase reporter construct (Promega,
Madison, WI). This fragment served as a template for PCR to
generate other deletion constructs. All constructs were tran-
siently transfected into H1299-V138 or cotransfected with
wild-type p53 expressing plasmid into the parental H1299
cells for luciferase reporter assays. Plasmid-expressing b-gal
was also included for internal controls of transfection effi-
ciency. The transfection was performed with LipofectAMINE
reagent (Invitrogen), according to the protocol supplied by
the manufacturer. The luciferase assay was performed
30 hours after transfection by using the Dual-Luciferase
Reporter Assay System (Promega) according to the manu-
facturer’s instruction and detected in a luminometer (Mi-
croLumat Plus; Berthold Tech Pforzheim/Germany). For
transfection in H1299-V138 cells, the incubation temperature
was shifted from 39jC to 32jC, 6 hours after transfection, to
allow the expression of wild-type p53. Luciferase activities
were measured after a 24-hour incubation at 32jC.
For TSA treatment experiment, parental H1299 cells were
transiently cotransfected with luciferase reporter constructs
of P-00/14 or p-05/18 (with empty vector pGL3-basic as a
control) and p53-expressing plasmid or the empty pcDNA3
vector as a control. Transfection efficiencywas normalized by
cotransfection with pRL-CMV, expressing Renillar luciferase
(Promega). Transfection was done directly in 96-well cell
culture plates with 20,000 cells/well plated in growth
medium 1 day before, using LipofectAMINE 2000. Each well
contained plasmids of 0.03 mg of P00/14 or p-05/18 or pGL-3,
0.18 mg of p53 or pcDNA3, and 0.001 mg of pRL-CMV. Cells
were subjected to TSA (Sigma) treatment for 6 hours starting
at 18 hours after transfection at various concentrations. The
luciferase activities were thenmeasured by Dual-Glo System
(Promega) on a TopCount (Packard Instrument, Meriden,
CT). The results from three independent experiments, with
each in triplicate, were expressed as fold induction after
normalization with transfection efficiency and pGL3-Basic
vector control.
Electrophoretic Mobility Shift Assay (EMSA)
The EMSA was performed as described previously [32,33].
The primers used were putative p53 binding oligonucleo-
tides found in the promoter region of SAK, including: 1) P-01
5V-AGCCTGGGCGACAGAGCGAG-3Vand its complementary
strand; 2) P-03 5V-TGCCCTGTTCCGTCAAGTCT-3Vand its
complementary strand; and 3) P-05 5V-GAACTAAA-
CTCTCCGCAGCGCT-3V and its complementary strand.
The oligonucleotides containing p53 binding sites from
the promoters of PTGF-b or p21 genes [5,7] served as posi-
tive controls. For supershift analysis, 1 mg of anti-p53 anti-
body Ab-1 (PAb421) or DO-1 was added to the reaction
mixture and incubated for 20 minutes before the addition of
32P-labeled oligonucleotide.
Chip PCR
Chromatin immunoprecipitation analysis used to assess
potential in vivo binding of p53 to the promoter of SAK was
performed as described [34,23,35]. The primer sequences
and their amplifying regions are given below. The primers
are in italics, and the consensus p53 binding sites or the
putative p53-repressive sites [22] are underlined with core
sequences in bold—for P21: GTGGCTCTGATTGGC-
TTTCTGGCCATCAGGAACATGTCCCAACATGTTG-
AGCTCTGGCATAGAAGAGGCTGGTGGCTA -
TTTTGTCCTTGGGCTGCCTGTTTTCAG; for Mdm2:
GGTTGACTCAGCTTTTCCTCTTGAGCTGGTCAAG-
TTCAGACACGTTCCGAAACTGCAGTAAAAGG
AGTTAAGTCCTGACTTGTCTCCAGCTGGGGCTATTT-
AAACCATGCATTTTCC; for P-01: CCAGCTACCCGGG
AGACTGAGGAAGGAGAATCGCTGGAACCCAGGAGAT-
GGAGGCTGCAGTGAGCCGAGATCGAGTCAC-
TGCACTCCAGCCTGGGCGACAGAGCGAG; for P-03/05
(P-03/05 contains two putative p53-repressive sites)
TGCCCTGTTCCGTCAAGTCTTAAACGCTTGACATT-
TTAAAATAGTTTTAAACCCTTTCCGGAATTAGAAGTGG-
TATTTCGGACCGTGAAGTAACCGATCAGCCAT-
AAGTGTCCCATCTTTAAGGCCTGCTCTTTTACCC
GTCTTGCAGAAGTTCTTCCGAGAGTGGGCCCGAGA-
CAGCCTCCCGCCCGAACTAAACTCTCCGCAGCGCT;
and for GAPDH: GTATTCCCCCAGGTTTACATGTTCCA-
ATATGATTCCACCCATGGCAAATTCCATGGCACC
GTCAAGGCTGAGAACGGGAAGCTTGTCATCAATGGAA-
ATCCCATCACCATCTTCCAGGAGTGAGTGGAAG-
ACAGAA.
SAK Silencing by RNAi
HeLa cells were seeded at 1.5 104 cells/well in a 12-well
plate in DMEM with antibiotic-free 10% FBS. Cells were
transfected from 16 to 20 hours later with RNAi Oligo,
SAK1 (276–297) AAGCCATGTACAAAGCAGGAA, or
SAK2 (2833–2844) AATGTTGGTTGGGCTACACAG using
Oligofect AMINE Reagent (Invitrogen) according to the
manufacturer’s instruction. After 48 hours of transfection,
cells in one well were harvested for RT-PCR analysis for
SAK expression, and cells in a duplicate well were photo-
graphed to evaluate morphologic signs of apoptosis. RNA
was isolated using Trizol reagents and reversely transcribed
into cDNA using random primers (Invitrogen). The cDNA was
amplified using SAK-specific primers PB01 5V-CACCCACAGA-
CAACA ATGCC-3V and PB02 5V-CTCCATACCCC-
TAGTCTTGCTC-3V to generate a 470-bp fragment. For
314 p53 Represses SAK Expression Li et al.
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loading control, a 253-bp fragment was amplified using
primers PBGD-283F 5V-GAGAAGAATGAAGTGGACCT-3V
and PBGD 536R 5V-AGGTTTCCCCGAATACTCC-3V for
gene-encoding porphobilinogen deaminase [35].
Establishment of SAK Stable Clones
A plasmid construct expressing FLAG-tagged human
SAK was a gift from Dr. Mano [36] and transfected into
U2-OS cells harboring a wild-type p53 [7]. Transfected
cells were subjected to G418 (600 mg/ml) selection for
2 weeks and a total of 12 stable clones was isolated by
ring cloning, followed by Western blot analysis using anti-
FLAG antibody (Sigma) to identify SAK-expressing clones,
as described previously [37].
DNA Fragmentation ELISA
Apoptosis was measured by DNA fragmentation–based
Cell Death ELISA Kit (Roche, Mannheim, Germany), accord-
ing to the manufacturer’s instruction. Briefly, HeLa cells were
seeded in a 96-well plate and cultured for 16 to 24 hours
before being transfected with different amounts of SAK RNAi
K1 or K2. Forty-eight hours posttransfection, both detached
and attached cells were collected by centrifugation and lysed
in 200 ml of lysing buffer by shaking at room temperature for
30 to 40 minutes. Following centrifugation, 20 ml of superna-
tant was used for the assay and read at OD405 nm.
DNA Fragmentation Gel Analysis
Two SAK-expressing stable clones, along with one vector
control, were treated with etoposide (25 mM) for 36 hours to
activate p53 [7]. Both detached and attached cells were
collected, lysed, and subjected to DNA fragmentation assay
as described previously [38].
Results
Chip Profiling Identified SAK as a p53-Repressive Gene
In an effort to identify genes responsive to p53-induced
growth arrest and/or apoptosis, we performed an Affymetrix
Genechip analysis of 12,000 genes (Human U95 Genechip
A; Affymetrix) using mRNA isolated from human H1299-
V138 cells expressing a temperature-sensitive p53 mutant.
p53 adapts a mutant conformation when cells are grown at a
nonpermissive temperature of 39jC but a wild-type confor-
mation at the permissive temperature of 32jC, which causes
cell growth arrest or apoptosis when given DNA-damaging
agents, such as etoposide [23,28]. H1299/Neo cells that
underwent neither growth arrest nor apoptosis at 32jC were
used as controls. Among 133 differentially expressed genes
that respond to both growth arrest and apoptosis conditions,
a new member of the PLK family, SAK (GenBank accession
no. Y13115 or MN_014264) was identified to be significantly
repressed by p53. The expression of this gene was not
changed in H1299/Neo cells under the same growth con-
ditions (Table 1). To confirm this finding, Northern analysis
was performed using SAK cDNA as a probe. As shown in
Figure 1A, SAKmRNA was highly expressed in growing cells
at 39jC (lane 1). SAK expression started to decrease as
early as 6 hours after shifting the temperature from 39jC to
32jC to induce wild-type p53 conformation in either the
absence or presence of etoposide (lanes 5–7 and 11–13).
SAK expression was not significantly changed in H1299-Neo
cells by the same treatment (Figure 1B), indicating that the
repression of SAK expression did not result simply from
temperature shifting nor from etoposide exposure. Because
temperature shift did not change p53 expression, but p53
activity in this transfected line [39], these results, therefore,
suggest that SAK could be repressed by a functional p53.
SAK Repression Was p53-Dependent
We then used two additional human tumor cell models to
assess more directly the role of p53 in the downregulation of
SAK. H460 lung carcinoma cells contain wild-type p53,
whereas H460/E6 are p53 negative due to the expression
of the human papilloma virus type 16 (HPV-16) E6 gene that
degrades p53 through a ubiquitin pathway [40]. Both H460
and H460/E6 cells were treated with etoposide for up to
24 hours to activate p53, followed by RNA isolation and
Northern blot analysis. As shown in Figure 2A, basal SAK
level was quite high in both cell lines. Treatment with etopo-
side dramatically decreased SAK expression in a time-
dependent manner in p53-positive H460 cells, but not in
p53-negative H460/E6 cells, indicating a direct relationship
between p53 status and downregulation of SAK expression.
The second pair of tumor cell model used was U2-OS (wild-
type p53) and Saos-2 (p53-null) human osteogenic sarcoma
cell lines. Treatment with etoposide caused, as expected, an
induction of p21 in U2-OS cells but not in Saos-2 cells,
indicating the activation of p53 by etoposide only in the U2-
OS cells (Figure 2B). In contrast to p21 induction, the SAK
expression was significantly repressed at 6 hours and further
repressed at 24 hours in U2-OS cells, whereas no significant
change in SAK expression was observed in Saos-2 cells.
Taken together, the results strongly suggested that down-
regulation of SAK expression is p53-dependent.
Lack of a Direct Binding of p53 to Several Putative
Binding Sites in the SAK Promoter
To clone the SAK promoter for a direct analysis of
transcriptional regulation of SAK by p53, we first identified
the transcriptional initiation site of the gene through a 5Vend
RACE experiment (Materials and Methods section). Se-
quencing analysis of 5Vend RACE clones revealed that the
longest piece of the 5Vuntranslated region of the gene ended
with a ‘‘T,’’ as indicated in Figure 3A. The results suggested a
transcriptional initiation site of ‘‘A’’ located at 242 bp up-
stream of the translation initiation codon in the human SAK
promoter (Figure 3B). A nucleotide ‘‘A,’’ which is located
303 bp upstream of the translation initiation codon, was
reported in mouse SAK promoter [41]. Based on the pub-
lished human genomic sequence around the SAK gene, a
pair of primers, P-00/P14, was designed to PCR-amplify a
1800-bp genomic fragment with 1.7 kb in the promoter region
and 100 bp downstream of the transcriptional initiation site
(Figure 5A).
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p53 usually transactivates its target genes through a direct
binding to the consensus binding sequence either in the gene
promoter or the introns [42]. It is still unclear whether
p53-induced gene repression requires a direct binding or
indirect recruiting of p53 to a promoter region. A novel p53
binding element for repression of a gene has been recently
described, which contains similar p53 consensus binding
sequences but in a different orientation [22]. A computer
search, allowing up to three mismatches, for possible p53
binding sites of either the typical consensus site or the novel
element identified three sequence elements at the promoter
region of the SAK gene (Figure 4A). To determine the
potential binding of p53 to these sites, we performed gel
mobility shift assay using nuclear extracts prepared from
H1299-V138 cells grown at 32jC in the presence of etopo-
side. Two known p53 binding elements from promoters of the
PTGF-b gene and the p21 gene, respectively, were used as
positive controls [5,7]. As shown in Figure 4B, p53 bound
specifically to the PTGF-b and p21 sites, but not to any of the
putative sites found in the SAK promoter. In addition, partially
purified p53 protein [32] or nuclear extract prepared from
etoposide-treated H460 cells also failed to bind to these sites
(data not shown), indicating a lack of direct p53 binding to
these sites in vitro. We also performed chromatin immuno-
precipitation assays to determine whether p53 binds to
these sites in vivo. As shown in Figure 4C, p53 bound to its
consensus sequence found in the p21 and Mdm2 genes
when it adapted a wild-type conformation (32jC) in the
presence of etoposide in H1299-V138 cells. No significant
signal of p53 binding to those sites found in the SAK promoter
was detected under the same assay conditions. Furthermore,
promoter walking using additional primer pairs that covered
the entire region from the transcription initiation site up to
nucleotide 1033 failed to detect any p53 binding (data not
shown). Taken together, these results indicated that p53
does not interact with putative binding sites found in the
promoter of SAK, implying that p53 may indirectly control
SAK expression.
p53-Induced SAK Repression Is Unlikely Mediated
through an Interference of p53 with Transcription
Factors, SP-1 and CREB
To understand the mechanism of repression, we made a
series of promoter luciferase constructs in an attempt to
identify the repression-responsive region in the SAK pro-
moter. The 1.8-kb fragment generated by a primer set of
P-00/P14 was used as a template to prepare other deletion
constructs, as presented in Figure 5A. H1299-V138 cells
were transfected with luciferase reporter driven by a different
length of SAK promoter sequence. After transfection, cells
were grown at 32jC for 24 hours to induce wild-type p53
conformation, followed by luciferase assay. As shown in
Figure 1.Wild-type p53-dependent repression of SAK expression. H1299-V138 (A) or H1299/Neo (B) cells were grown either at 398C (mutant p53 status) or 328C
(wild-type p53 status) for 6, 16, and 24 hours in the presence of DMSO or etoposide (25 M) as indicated. Cells were harvested and RNA were prepared for
Northern analysis (15 g of total RNA) using probes against SAK. GAPDH was used as a loading control.
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Figure 5B, wild-type p53 induced an up to three-fold reduc-
tion of luciferase activity. Because the degree of reduction of
luciferase activity was similar between constructs P-00/P14
and P-05/P14, the promoter sequence flanking 1698 to
131 contributed little to p53-induced repression. Thus, the
responsive cis elements are likely located within the proximal
region of nucleotides 131 to +102. To define the cis
element(s), we performed a computer search for potential
transcription factor binding sites. The putative binding sites
of SP-1 and CREB were identified, among several others,
such as NRF1 and NRF2. A series of deletion luciferase
reporters was generated, as shown in Figure 5A, with SP-1
and CREB sites indicated and tested for their p53-dependent
activity. As expected, no luciferase activity and p53 repres-
sion was detected with the construct P-29/14-luc due to lack
of promoter sequence (Figure 5C). This further narrowed
down the responsive element(s) to the upstream 131-bp
promoter sequence. A 12-fold basal activity and a similar
two-fold repression by p53 seen in constructs P-05/18-luc
and P-23/18-luc indicated that the promoter sequence be-
tween 131 and 100 did not contribute to SAK regulation.
Deletion of SP-1 binding site alone almost completely abol-
ished the promoter activity (from 12- to 2-fold) as seen in
construct P-27/18-luc, indicating a requirement of the SP-1
factor for basal transcriptional activity. However, the lucifer-
ase activity driven by this fragment was still repressed by up
to two-fold by p53. Deletion of CREB site alone caused a
two-fold reduction of basal transcriptional activity (from 12- to
6-fold), but again a further two-fold repression by p53, as
shown in construct P-05/22-luc. Deletion of both SP-1 and
CREB sites, as seen in construct P-27/22-luc, reduced basal
activity from 12- to 2-fold, and p53 had no repressive effect
(Figure 5C). Thus, it appeared that two-fold repression of the
SAK promoter by p53 required the presence of both SP-1
and CREB binding sites. To further investigate the possibility
that p53-induced repression of the SAK promoter may be
Figure 3. 5VRACE used to determine the transcriptional initiation site of the SAK gene. (A) Sequence demonstration of transcription initiation site of the SAK gene.
5VRACE was performed with Ambion’s FirstChoice RLM-RACE kit according to the manufacturer’s instructions. The transcription initiation site was determined by
comparing the sequences immediately after the 5VRACE adapter (5V-GAACACTGC GTTTGCTGGCTTTGATGAAA-3 V) to the SAK gene sequence through the
evidence viewer from NCBI. The SAK mRNA start was indicated. (B) DNA sequence of 171 to +250 of the SAK gene. The bold ‘‘A’’ and ‘‘ATG’’ indicate the
transcription initiation site (+1) and the translation starting codon, respectively. The potential SP-1 and CREB binding sites are in bold face and underlined.
Figure 2. SAK repression is p53-dependent. (A) Human lung carcinoma line,
H460 (wild-type p53), and its E6 transfectant, H460/E6 (p53-negative due to
E6-mediated p53 degradation), and (B) human osteogenic sarcoma lines,
Saos-2 (p53-null) and U2-OS (wild-type p53), were treated with etoposide
(25 M) for 0, 6, and 24 hours to activate p53. Cell pellets were subjected to
RNA isolation and Northern analysis (15 g of total RNA) using probes
against SAK or p21. The 18S ribosomal RNA was used as a loading control.
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mediated through an interference of p53 with transcription
factors SP-1 and CREB for their binding to respective binding
sites, we performed cotransfection experiments using lucif-
erase reporters driven by P-00/14, P-23/18, or P-05/18 and
plasmids expressing SP-1 or CREB in combination with p53.
Cotransfection of neither SP-1 nor CREB reversed p53-
induced two-fold reduction of SAK promoter activity (data
not shown), indicating that interference of p53 with transcrip-
tion factors SP-1 or CREB is unlikely a direct cause of SAK
repression by p53. However, these two binding sites could
be a part of cis elements required for basic transcription
machinery to bind for basal promoter activity as well as for
p53 repression.
p53-Induced SAK Repression Can Be Rescued by the
HDAC Inhibitor, TSA
It has been previously shown that p53 can directly interact
with some factors of the basal transcription machinery such
as TBP [43,21], which facilitates a recruitment of the mSin3a/
HDAC repressor complex to repress the transcription [44],
and such repression can be reversed with an HDAC inhibitor
in the case of p53 repression of prostate-specific antigen
(PSA) [45]. To determine the possible involvement of HDAC
in p53-mediated SAK repression, we use luciferase reporters
driven either by a 1.8-kb promoter fragment (P-00/14) or a
131-bp fragment (P-05/18), which showed the highest pro-
moter activity. The reporter constructs were cotransfected
with p53 into parental H1299 cells, followed by treatment with
Trichostatin A (TSA) with various concentrations for 6 hours.
As shown in Figure 6A, p53-induced f3.5-fold repression
of a 1.8-kb SAK promoter activity can be largely reversed
by TSA in a dose-dependent (up to 0.6 mM) manner. More
significantly, the 131-bp SAK promoter repression by p53
was completely reversed by TSA, again in a dose-dependent
manner (Figure 6B). Thus, it appeared that SAK promoter re-
pression by p53 is mainly mediated through a p53-mediated
recruitment of HDAC transcription repressor.
SAK Silencing by RNAi induced Apoptosis
To understand the biologic significance of SAK repression
by p53 during apoptosis, we knocked down SAK expression
using RNAi and looked for phenotype changes. HeLa cells
were transfected with two SAK RNAi (K1 and K2). Forty-
eight hours posttransfection, cells were harvested, RNA
were prepared, and SAK expression was determined by
RT-PCR. As shown in Figure 7A, K1, but not K2, caused a
significant reduction of endogenous SAK expression. Ac-
companying the SAK reduction, morphologic signs of apop-
tosis appeared in K1-transfected, but not K2-transfected,
cells (Figure 7B). Quantitative DNA fragmentation assay
showed that indeed K1, but not K2, RNAi induced apoptosis
in a dose-dependent manner (Figure 7C). Thus, SAK re-
pression likely contributes to p53-induced apoptosis.
SAK Overexpression Attenuated p53-Induced Apoptosis
If SAK repression is critical for p53-mediated apoptosis
induction, one would expect that overexpression of SAK
should block or attenuate p53 effect. To test this hypothesis,
we went on to establish SAK stable lines by transfecting
a plasmid-expressing FLAG-SAK into wt p53-containing U2-
OS cells, along with the vector control. After G418 selection,
we isolated 12 stable clones by ring cloning and tested their
SAK expression by Western blot analysis with anti-FLAG
antibody. As shown in Figure 8A, two independent positive
clones (Cl. 5 and Cl. 8) expressed an expected size of SAK
band at 98 kDa [36], compared to vector control clones. Other
10 stable clones failed to express SAK (data not shown).
These three clones were then subjected to etoposide treat-
ment to induce p53 as shown previously [46,7], followed
Figure 4. p53 failed to bind to three putative p53 binding sites in the SAK
promoter. (A) Listed are the sequences of the p53 consensus binding site for
activation (line 1) and repression (line 2) [23] and three putative p53 binding
sites within the SAK promoter region (lines 3–5). R = purine, Y = pyrimidine,
W = A/T, H = head, T = tail. The mismatches in SAK promoter sequences are
indicated with lower case letters and the core sequences are indicated in
bold face. (B) In vitro gel retardation assay. The assay was performed as
detailed in the Materials and Methods section. The probe PTGF (5V-AGCC-
ATGCCCGGGCAAGAAC-3 V) and its complementary strand from the pro-
moter of the PTGF- gene [54], and p21 (5V-GAACATGTCCCAACATGTT
G-3V) and its complementary strand from the promoter of p21 gene [11], were
used as positive controls in the assay. p53/Ab indicates the supershifted
complex in the presence of p53 antibody, pAb421. (C) In vivo chromatin
immunoprecipitation. p21 and Mdm2 are used as positive controls, and
GAPDH is used as a negative control. Since two putative p53 binding sites,
P-03 and P-05, are adjacent to each other, only one pair of PCR primers
was used to detect potential p53 binding to any one of them. Total cell
extracts were prepared from H1299/Neo (lane 1) and H1299-V138 (lanes 2
and) cells treated with either DMSO or 25 M etoposide for 24 hours at
39jC or 32jC. The assays were performed as detailed in the Materials and
Methods section.
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by a gel assay for DNA fragmentation, a hallmark of apop-
tosis. As shown in Figure 8B, etoposide treatment signifi-
cantly induced DNA fragmentation in U2-OS vector control
cells. The degree of DNA fragmentation was significantly
reduced in both SAK-overexpressing clones, indicating that
SAK overexpression attenuates p53-induced apoptosis.
Discussion
Proposed mechanisms for p53-induced gene repression
fall into three general categories. Firstly, p53 may directly
bind to a promoter through either a consensus binding
site [22] or other sites that are overlapped with some cis
elements such as E2F, SP-1, or HNF3, which are required
Figure 5. Define the responsive elements in the SAK promoter to p53-induced SAK repression. (A) Diagram to show a series of luciferase reporters driven by a
different length of SAK promoter sequence. An arrow at position +1 indicates the transcription initiation site. SP-1 and CREB binding sites in the proximal region of
the transcription start site are shown as filled bars. (B) p53 represses SAK promoter activity. H1299-V138 cells were transiently transfected with various luciferase
reporter constructs as indicated followed by incubation at 398C or 328C for 24 hours before being harvested for luciferase activity assay. Shown are fold activation
of promoter constructs in either the presence or absence of wild-type p53, normalized to the activation of the pGL-3 empty vector. Results are from three
independent transfections, each performed in duplicate and expressed as mean ± SEM. (C) SP-1 and CREB binding sites mediated by two-fold repression of the
SAK promoter. Parental H1299 cells were cotransfected with either wild-type p53 or pcDNA3 vector control, plus various luciferase constructs as indicated.
Twenty-four hours following transfection, cells were harvested and assayed for luciferase activity. The bar graph shows fold activation of various constructs when
compared with the empty luciferase construct, pGL-3, from three independent transfections, each performed in duplicate and expressed as mean ± SEM.
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for transactivation of the gene [19,47,48]. Secondly, p53
may interact with a transcription factor in the promoter
and interfere with its normal function of transactivation.
Examples include p53 repression of Cdc2, cyclin B, and
Cdc25C by interaction with NF-Y [49,50]; p53 downregula-
tion of human MMP1 and metastasis-associated laminin
receptor promoters through AP-1 and AP-2, respectively
[51,52]; and p53 inhibition of the albumin gene and the glyco-
protein hormone common a subunit gene through C/EBPb
and CBP/p300, respectively [53,54]. Thirdly, p53 may di-
rectly interact with some factors of the basal transcription
machinery such as TBP [43,21]. The binding of p53 to these
factors could recruit an HDAC complex to the minimal
promoter region and cause a repression of transcription
[44]. Such repression may be reversed in the presence of
HDAC inhibitors [45].
Through chip profiling, we have identified SAK, a PLK, as
a p53-repressed gene. We further validated that SAK is
indeed repressed by p53 in multiple human tumor models
using a classic Northern analysis. Although three p53 con-
sensus binding sites were identified in the SAK gene pro-
moter, p53 failed to bind to any of these sites as assayed by
in vitro gel retardation assay and in vivo chromatin immuno-
precipitation. Further characterization of SAK promoter
through transcription-coupled luciferase assay revealed that
p53 repression of SAK expression cannot be reversed by
cotransfection of SP-1 and CREB, although these two tran-
scription factor binding sites appeared to mediate a two-fold
SAK repression by p53. However, p53 repression of SAK
promoter can be largely reversed by TSA, a potent inhibitor
of HDACs. Thus, SAK repression by p53 is not mediated
through direct promoter binding, unlikely through interfer-
ence of p53 with SP-1 and CREB, but rather through the
recruitment of HDAC transcriptional repressors.
SAK belongs to a PLK family with other members in-
cluding PLK1, PLK2/Snk, and PLK3/Fnk/Prk. The PLKs are
known to play pivotal roles in cell cycle regulation, specifi-
cally in the control of entry and exit of mitosis [55–57]. Like
other family members, SAK contains a Ser/Thr kinase
domain at the N-terminus and one highly conserved polo
box at the C-terminus of the protein [26,58]. SAK expres-
sion appeared to be required for cellular exit from mitosis
through the APC-dependent inactivation of the Cdc2/
cyclin B complex [26]. It has been previously shown that
SAK expression was subjected to cell cycle regulation in
NIH 3T3 fibroblast cells [24]. We performed a similar
experiment in H1299-Neo epithelial-originated cancer cells
by arresting cells at the G2/M phase with nocodazole for
16 hours, followed by cell release from the G2/M phase
Figure 6. TSA rescued SAK repression by p53. Parental H1299 cells were
plated in a 96-well plate and transfected with luciferase reporters driven
either by a 1.8-kb SAK promoter (P-00/14) (A) or a 131-bp promoter fragment
(P-05/18) (B) in the absence or presence of p53, along with pRL-CMV, which
expressed Renillar luciferase for transfection efficiency control, as described
previously [54]. Eighteen hours posttransfection, cells were treated with
indicated concentrations of TSA for 6 hours. Cells were lysed in a plate and
subjected to luciferase assay. Results from three independent transfections,
each in triplicate, were presented as mean ± SEM after normalization with the
empty luciferase vector, pGL3-basic, and pRL-CMV controls.
Figure 7. SAK silencing through RNAi-induced apoptosis. HeLa cells were
left untransfected or transfected with two individual RNAi oligonucleotides
(200 nM), K1 and K2, by oligofectamine for 48 hours, followed by RNA
isolation and RT-PCR analysis with a housekeeping gene PBGD as the
loading control (A), or morphological observation for sign of apoptosis (B),
and DNA fragmentation ELISA (C).
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by growth in fresh serum-containing media. Cells were
collected at 3, 6, 8, 16, 18, 20, 22, and 24 hours post–
nocodazole release. The cell samples were split into two
portions: one portion was for FACS analysis to monitor cell
cycle progression, whereas the other portion was for RNA
isolation, followed by RT-PCR analysis to monitor SAK
expression. FACS analysis revealed that cells started to
enter the G1 phase 3 hours post–nocodazole release and
reached the peak at 8 hours. Cells started to enter the
S phase 16 hours post release and reached the peak at
22 hours. In all cell samples collected, no significant change
in SAK expression was observed (data not shown). Thus,
SAK expression appeared not to be subjected significantly
to cell cycle regulation in H1299 lung carcinoma cells.
It has been previously reported that inhibition of SAK
expression using antisense murine SAK suppressed the cell
growth of Chinese hamster ovary (CHO) cells [24], whereas
transient overexpression of SAK induced multinucleation
and resulted in suppression of CHO cell growth as well [25].
Thus, it appears that the SAK expression level is crucial for
cell growth. It has also been reported that changes of
intracellular levels of other PLKs were also involved in the
control of cell growth. For example, PLK1, when fused to an
antennapedia peptide and efficiently internalized into cells,
caused an inhibition of cancer cell proliferation [59], whereas
downregulation of PLK1 by antisense induced the growth
inhibition of cancer cells [60]. Inhibition of PLK1 activity also
contributed to apoptosis induced by b-hydroxyisovalerylshi-
konin, a plant isolate [61]. Furthermore, PLK3 induces cell
cycle arrest and apoptosis through perturbation of micro-
tubule integrity [62]. Moreover, PLK2 was recently found to
be a novel p53 target gene, and that RNAi silencing of
PLK2 leads to mitotic catastrophe in taxol-exposed cells
[63]. Finally, and most importantly, a recent report showed
that PLK1 was also repressed by p53 in a direct binding-
independent manner, and that RNAi silencing of PLK1
induced apoptosis [64], which is consistent with our obser-
vation in SAK. In addition, PLK1 was found to actually bind to
p53 and block p53-induced apoptosis [65], consistent with
our observation that SAK overexpression attenuated p53-
induced apoptosis. Taken together, SAK, like its family
member PLK1, can regulate p53 apoptosis function, and its
downregulation may be necessary for p53 to induce apop-
tosis. Thus, SAK appears to be a promising cancer target for
p53-dependent induction of apoptosis.
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